Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(ALNY, NHPR, CLNO, VTSS, ASE) Stocks in Review by CRWEPicks.com

signup3m

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, reported its consolidated financial results for the second quarter 2011. he net loss according to accounting principles generally accepted in the U.S. (GAAP) for the second quarter of 2011 was $13.8 million, or $0.33 per share on both a basic and diluted basis (including $4.2 million, or $0.10 per share of non-cash stock-based compensation expense), as compared to a net loss of $14.6 million, or $0.35 per share on both a basic and diluted basis (including $5.1 million, or $0.12 per share of non-cash stock-based compensation expense), for the same period in the previous year. Revenues were $20.6 million for the second quarter of 2011, as compared to $26.6 million for the same period last year. Revenues for the second quarter of 2011 included $14.0 million of collaboration revenues related to the company's alliance with Roche, $5.5 million of revenues from the company's alliance with Takeda Pharmaceuticals Company Limited, and $1.1 million of expense reimbursement, amortization, and/or license fee revenues from Novartis, Cubist Pharmaceuticals, Inc., Biogen Idec Inc., and other sources.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi).

***********************************************

 

Read more at: http://crwepicks.com/?p=17764